Meeting
2016 Gastrointestinal Cancers Symposium
KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.
Authors
Dung T. Le
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Dung T. Le , Takayuki Yoshino , Dirk Jäger , Thierry Andre , Johanna C. Bendell , Ruixue Wang , SoonMo Peter Kang , Minori Koshiji , Luis A. Diaz Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02460198
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS787)
DOI
10.1200/jco.2016.34.4_suppl.tps787
Abstract #
TPS787
Poster Bd #
O18
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
KEYNOTE-164: phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.
First Author: Dung T. Le
Poster
2022 ASCO Annual Meeting
Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC).
First Author: Mohamed E. Salem
Poster
2016 ASCO Annual Meeting
KEYNOTE-177: first-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.
Poster
2016 Gastrointestinal Cancers Symposium
KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
First Author: Luis A. Diaz Jr.